Page last updated: 2024-09-05

sorafenib and sb 225002

sorafenib has been researched along with sb 225002 in 2 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(sb 225002)
Trials
(sb 225002)
Recent Studies (post-2010) (sb 225002)
6,5207305,25192073

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)sb 225002 (IC50)
C-X-C chemokine receptor type 1Homo sapiens (human)0.022
C-X-C chemokine receptor type 2Homo sapiens (human)0.0623

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chu, B; Jiang, Y; Li, Q; Liu, Z; Luo, J; Shi, Z; Xin, Q; Ye, L; Zhan, F; Zhang, X; Zhu, Q1
Devapatla, B; Sharma, A; Woo, S1

Other Studies

2 other study(ies) available for sorafenib and sb 225002

ArticleYear
Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
    European journal of medicinal chemistry, 2021, Dec-15, Volume: 226

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pyridazines; Receptors, Interleukin-8B; Structure-Activity Relationship; Triazoles

2021
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2015